GenoScreen develops advanced DNA analysis services and technologies for research and innovation in the life sciences. Thanks to constant investment in R&D and specialization in molecular microbiology, our evolution has been built in three stages:

 

A look back at the key moments in our history

Slide 1

2001

Creation of GenoScreen
RIO-certified platform

2004

Launch of an R&D activity
INPI Trophy
CIR accreditation

2006

First publication
First patent filed

2007

OTC patent filed Biomarker for Alzheimer's disease
Launch of MIRU typing service
for M. tuberculosis (tuberculosis)

2009

Export sales exceed 30%
Platform awarded "IBISA" label
Deloitte Technology Fast 50 Trophy
Joining the Oséo excellence community

2010

Release of the “Microsatellite Bank” offer
Launch of the “MEDIALZ” project (Alzheimer's disease)

2011

Patho-Ngen-Trace" project launched (FP VII)
INPI prize for innovation and creativity

2012

EQUIPEX validated sequencing platform
Optimization of metagenomics services

2013

Launch of industrial R&D partnerships

2014

Launch of the MIRU-VNTR kit
Launch of Metabiote® engineering
GCLP (Good Clinical Laboratory Practice) recognition for microbiota analysis

2015

ISO 9001 Certificates

2016

ISO 13485 Certificates

2018

DIAMA" project (Evaluation and validation
of the Deeplex® Myc-TB test in Africa and Europe)

2019

Launch of the Deeplex® Myc-TB kit
Participation in the “GenoSol” project (mapping of French soils)
“PEOPLE” project, funded by the EDCTP (European & Developing Countries Clinical Trials Partnership)

2020

Launch of the Brucella MLVA-16 offer
CE-IVD marking for Deeplex® Myc-TB
More than 70 publications with GenoScreen researchers listed as authors

2021

Launch of the “Seq&Treat” project under the guidance of FIND and WHO

2022

Launch of sequencing services
on the Oxford Nanopore platform

2023

Establishment of a partnership with Illumina
Launch of Deeplex® Myc-Lep and Deeplex® HelP
Launch of GenoBiome®

2024

The WHO validates and recommends tNGS technology,
developed from Deeplex® engineering kits
Export sales reach 50%

2025

Launch of Deeplex® TB XL
Over 80 publications with GenoScreen researchers listed as authors

Développement de qPCR
sur mesure

Design in silico, validation in vitro,
optimisation des conditions expérimentales

Optimisation et validation de
designs existants

Détermination des seuils LOD/LOQ,
tests sur matrices complexes

Aide au transfert et validation
sur vos équipements

Assistance pour l'intégration de la méthode
sur votre matériel

Évaluation complète
des performances analytiques

Détermination des seuils LOD/LOQ,
tests sur matrices complexes

By continuing your visit to this site, you accept the use of statistics cookies